Armour Thyroid Pharmacokinetics (ADME): How Natural Desiccated Thyroid Works in the Body

What Is Armour Thyroid and Why Does Its Dual-Hormone Composition Matter?

Armour Thyroid is a prescription oral tablet made from desiccated porcine thyroid glands. Each 65 mg grain contains approximately 38 mcg of T4 and 9 mcg of T3, producing a T4:T3 mass ratio near 4:1. Synthetic levothyroxine contains no T3 at all, relying entirely on peripheral deiodination to generate the active hormone. That single structural difference drives nearly every pharmacokinetic distinction between the two treatments.

The Biological Origin Matters for ADME

Because Armour Thyroid is an animal-derived glandular extract, its T4 and T3 content is standardized by the United States Pharmacopeia (USP) to iodine content, not by direct assay of T4 and T3 concentrations. This means batch-to-batch variability in exact hormone ratios is possible, a point the FDA has acknowledged in its review documents. Clinicians monitoring patients on NDT should interpret TSH, free T4, and free T3 values in the context of that variability.

Comparison to Levothyroxine at the Molecular Level

T3 (liothyronine) binds the thyroid hormone receptor with roughly 10 times greater affinity than T4, making it the predominately active species at the nuclear receptor level. T4 functions largely as a prohormone. In patients with impaired peripheral deiodinase activity, conversion of T4 to T3 may be suboptimal, which provides one biochemical rationale for dual-hormone therapy. The NIH MedlinePlus thyroid physiology overview provides foundational receptor-binding data supporting this model.

Absorption: How T4 and T3 Enter the Bloodstream

T3 absorbs rapidly. T4 absorbs more slowly and less completely. Taking Armour Thyroid on an empty stomach maximizes T4 uptake, because food, calcium, iron supplements, and antacids can reduce T4 bioavailability by 20 to 40 percent.

T4 Absorption Kinetics

Oral T4 bioavailability ranges from 40 to 80 percent in healthy adults, with most absorption occurring in the proximal small intestine (jejunum and ileum). Benvenga et al. (2004) demonstrated that coffee, dietary fiber, and calcium carbonate each significantly reduced levothyroxine absorption. The same mechanisms apply to the T4 fraction in NDT. Peak serum T4 concentrations occur roughly 2 to 4 hours after ingestion, though the serum curve is relatively flat due to the long T4 half-life of 6 to 7 days.

Patients with short bowel syndrome, celiac disease (even subclinical), or H. Pylori-related gastritis may need meaningfully higher doses to achieve equivalent systemic exposure, because mucosal surface area and gastric pH directly modulate T4 uptake.

T3 Absorption Kinetics

T3 absorption is substantially more complete than T4, with oral bioavailability approaching 95 percent. This efficiency occurs because T3 is more lipophilic and less dependent on the intestinal transporters that govern T4 uptake. Peak serum T3 concentrations (Tmax) occur within 2 to 4 hours of dosing. Because NDT delivers a discrete exogenous T3 bolus with each dose, patients experience a daily serum T3 peak followed by a trough, a pattern absent in patients on levothyroxine-only therapy who derive T3 exclusively from steady-state peripheral conversion. Leese et al. (1992) documented this pulsatile T3 pattern in subjects receiving combined T4/T3 therapy and noted the associated short-duration supraphysiologic T3 surge.

Clinical Dosing Implication: Empty Stomach Rule

The standard clinical instruction is to take Armour Thyroid 30 to 60 minutes before breakfast, or at least 3 to 4 hours after any calcium- or iron-containing supplement. Some clinicians advocate bedtime dosing to sidestep food interactions entirely. A 2010 randomized crossover trial published in Archives of Internal Medicine (Bolk et al.) found that bedtime levothyroxine dosing produced higher free T4 and lower TSH than morning dosing, a finding that may extrapolate to the T4 component in NDT, though direct bedtime-dosing trials specific to Armour Thyroid remain limited.

Distribution: Where T4 and T3 Go After Absorption

Both T4 and T3 are extensively protein-bound in plasma. Greater than 99 percent of circulating T4 and T3 is bound to three carrier proteins: thyroxine-binding globulin (TBG), transthyretin (TTR, also called thyroxine-binding prealbumin), and albumin. Only the free fraction (free T4, free T3) is biologically active and enters cells via membrane transporters.

Protein Binding Specifics

TBG carries approximately 75 percent of bound T4 and has a higher affinity for T4 than T3. Albumin, despite its lower affinity, carries a significant reserve capacity. Conditions that alter TBG levels directly shift the total T4 and T3 values without changing free hormone concentrations. Estrogen (including oral contraceptives and pregnancy) raises TBG synthesis, increasing total T4 while free T4 remains stable. Androgens and glucocorticoids suppress TBG. Patients on NDT who start or stop oral estrogen therapy may need TSH re-checks within 6 to 8 weeks.

Volume of Distribution

The apparent volume of distribution (Vd) for T4 is approximately 10 to 11 liters in a 70 kg adult, reflecting its relatively restricted distribution due to tight protein binding. T3's Vd is substantially larger, estimated at 38 to 40 liters, indicating broader tissue penetration. T3 enters cells via monocarboxylate transporter 8 (MCT8) and organic anion transporting polypeptide 1C1 (OATP1C1). Genetic variants in MCT8 (SLC16A8 gene) can impair T3 cellular uptake, a rare but documented cause of tissue-level hypothyroidism despite normal serum values. Friesema et al. (2004) first characterized MCT8 mutations in this context.

Metabolism: Deiodination, Conjugation, and Deamination

Thyroid hormone metabolism is dominated by deiodination. The three deiodinase enzymes (D1, D2, D3) control both the activation and inactivation of thyroid hormones, and their tissue-specific distribution explains why serum TSH does not always reflect intracellular thyroid hormone status.

Deiodination Pathways

Type 1 deiodinase (D1), expressed primarily in liver and kidney, catalyzes the outer-ring deiodination of T4 to produce the active T3. It also converts T3 to diiodothyronine (T2). Type 2 deiodinase (D2), expressed in brain, pituitary, brown adipose tissue, and thyroid, preferentially generates intracellular T3 from local T4, shielding these tissues from serum T3 fluctuations. Type 3 deiodinase (D3) inactivates both T4 (to reverse T3, rT3) and T3 (to T2).

Because Armour Thyroid delivers pre-formed T3, patients bypass the D1/D2 conversion step entirely for a portion of their daily T3 supply. This is pharmacologically significant for the minority of patients who carry loss-of-function variants in the DIO2 gene (encoding D2), who may produce suboptimal T3 from T4 alone. Panicker et al. (2009) found that a common DIO2 polymorphism (Thr92Ala) was associated with worse psychological well-being in patients on levothyroxine monotherapy.

Conjugation and Deamination

A smaller proportion of T4 and T3 undergoes hepatic glucuronidation and sulfation, producing conjugates excreted in bile. Enterohepatic recirculation returns some of these conjugates to the systemic pool after intestinal bacterial deconjugation. Deamination of the alanine side chain produces thyronamines and acetic acid derivatives (notably triiodothyroacetic acid, Triac), which are biologically active at trace concentrations. These minor pathways contribute to intraindividual variability in thyroid hormone levels.

Drug Interactions Affecting Metabolism

Rifampicin and phenytoin induce hepatic glucuronosyltransferases and cytochrome P450 enzymes that accelerate thyroid hormone catabolism, often necessitating NDT dose increases of 25 to 50 percent in patients on those agents. Amiodarone inhibits D1, raising serum T4 while reducing T3 production, and alters TSH interpretation. Haugen et al. (2016 ATA Guidelines) address these interactions explicitly in the context of hypothyroidism management.

Elimination: Half-Lives, Renal Excretion, and Clinical Consequences

T4's long half-life (6 to 7 days) allows once-daily dosing and smooths out missed-dose pharmacokinetics. T3's short half-life (approximately 1 day) means that a missed dose produces a measurable serum T3 trough within 24 to 48 hours.

T4 Half-Life and Steady State

T4 reaches steady-state serum concentrations after approximately 4 to 5 half-lives, which translates to 4 to 6 weeks of daily dosing. Dose adjustments should not be assessed by TSH until at least 6 weeks have elapsed. In hypothyroidism, the half-life may extend slightly because metabolic clearance is slowed. Conversely, in hyperthyroidism or high-dose exogenous thyroid states, clearance accelerates and half-life shortens.

T3 Half-Life and the Pulsatile Pattern

The approximately 1-day T3 half-life produces the daily peak-and-trough phenomenon unique to NDT therapy. Serum T3 drawn 2 to 4 hours after a morning NDT dose may appear supraphysiologic even when the 24-hour average T3 is within range. The American Thyroid Association's 2016 Guidelines on Hypothyroidism specifically note this timing artifact and recommend drawing T3 levels at trough (immediately before the next dose) rather than at peak to avoid misclassifying patients as over-replaced.

Renal Excretion

Free T4 and T3 are filtered at the glomerulus but extensively reabsorbed due to their lipophilicity and protein binding. Net renal excretion is minor. The dominant excretory route is hepatic: glucuronide and sulfate conjugates enter bile, pass into the intestinal lumen, and are partially reabsorbed (enterohepatic circulation) or eliminated in feces. Patients with severe renal impairment do not typically require dose adjustment for Armour Thyroid on the basis of renal clearance alone, though comorbid changes in TBG and albumin in chronic kidney disease can alter free hormone fractions.

Clinical Trial Evidence: NDT vs. Levothyroxine Pharmacokinetic Outcomes

The most rigorous head-to-head comparison between NDT and levothyroxine was conducted by Hoang et al. (2013), published in the Journal of Clinical Endocrinology and Metabolism.

Hoang et al. 2013 (JCEM)

In this randomized, double-blind, crossover trial (N=70 hypothyroid adults), Hoang et al. compared NDT to levothyroxine over two 16-week treatment periods. Both arms achieved similar mean TSH values. However, NDT-treated patients showed significantly higher serum T3 concentrations and lower serum T4 concentrations compared to levothyroxine, reflecting the direct T3 delivery and the absence of excess T4 substrate for peripheral conversion. Fifty-two percent of participants preferred NDT at the study's end, versus 19 percent who preferred levothyroxine (P<0.001). Body weight was modestly lower in the NDT arm (mean difference: 0.46 kg, not clinically dramatic but statistically significant). No significant differences in lipid profiles or bone density were detected during the 32-week study window.

Mechanistic Interpretation of the Hoang Data

The higher T3 and lower T4 serum pattern on NDT directly confirms the pharmacokinetic prediction: exogenous T3 delivery bypasses the T4-to-T3 conversion step, raising T3 without requiring high T4 levels. The pulsatile T3 kinetics also likely contributed to the patient-preference signal, though whether that reflects genuine symptom benefit or a transient stimulant-like effect of the T3 peak remains debated.

Interpreting Labs in NDT Patients: A Timing Framework

Clinicians monitoring patients on Armour Thyroid should use the following draw-time framework to avoid pharmacokinetic misinterpretation:

• TSH: Draw any time; reflects integrated pituitary response over days to weeks.
• Free T3: Draw at trough (immediately before the next morning dose) to avoid the post-absorption peak confounding the result.
• Free T4: Draw any time; T4's long half-life minimizes timing effects.
• Total T3: Same trough recommendation as free T3.

Failure to time the T3 draw correctly is the most common source of apparent "over-replacement" in otherwise well-controlled NDT patients.

Mechanism of Action: What Happens After T3 Enters the Cell

Once free T3 crosses the cell membrane via MCT8 and OATP1C1, it binds thyroid hormone receptors (TR-alpha and TR-beta) in the cell nucleus. Receptor-hormone complexes associate with thyroid hormone response elements (TREs) on DNA, regulating transcription of genes governing basal metabolic rate, cardiac contractility, lipid metabolism, neurological development, and thermoregulation.

TR-alpha predominates in cardiac and skeletal muscle. TR-beta predominates in liver, kidney, and the pituitary gland. The pituitary's sensitivity to T3 via TR-beta is what drives TSH suppression when T3 levels rise. Because NDT produces a daily T3 surge, TSH may be relatively suppressed at the time of the peak even at replacement doses, a pattern that can mislead clinicians into unnecessary dose reductions.

T4, acting via nuclear TR after intracellular conversion to T3 by D2, provides a more stable background thyroid receptor occupancy. Together, the two hormones in NDT provide both the rapid genomic signaling of T3 and the sustained prohormone reservoir of T4.

Special Populations: How ADME Changes Across Patients

Pregnancy

TBG rises sharply in the first trimester, increasing the total hormone pool needed to maintain stable free T4 and free T3. Pregnant patients on Armour Thyroid typically need a 25 to 30 percent dose increase by weeks 4 to 6 of gestation. The Endocrine Society's 2012 Clinical Practice Guidelines on Thyroid Disease in Pregnancy recommend maintaining TSH below 2.5 mIU/L in the first trimester for hypothyroid patients, regardless of the thyroid preparation used.

Older Adults

Metabolic clearance of both T4 and T3 slows with age due to reduced hepatic blood flow and diminished deiodinase activity. Cardiac sensitivity to T3-mediated chronotropy also increases. Starting doses in patients over 65 years are generally 25 to 50 percent lower than standard adult doses, with incremental titration over 8 to 12 weeks. The daily T3 surge from NDT may carry a higher arrhythmia risk in older patients with subclinical or overt cardiac disease.

Patients With Impaired DIO2 Activity

The Thr92Ala DIO2 variant is present in roughly 12 to 16 percent of the general population and may reduce intracellular T3 generation from T4. For these patients, the pre-formed T3 in NDT could theoretically compensate for reduced D2 activity, though large prospective genotype-stratified trials are lacking. Panicker et al. (2009) provide the strongest current evidence linking this polymorphism to patient-reported outcomes on standard levothyroxine therapy.

Formulation Considerations: How the Tablet Affects ADME

Armour Thyroid tablets contain an excipient matrix that may affect dissolution rate. Unlike some liquid levothyroxine preparations, the tablet must dissolve in gastric fluid before the hormone fractions become available for intestinal absorption. Tablet crushing does not meaningfully accelerate T4 absorption because the rate-limiting step is intestinal transport, not tablet disintegration.

The USP standardization of NDT to total iodine content (rather than direct T3/T4 assay) means that actual hormone delivery can vary by a small percentage between lots. Patients who notice symptom changes after a pharmacy switches NDT lots should have TSH and free T3 re-checked within 4 to 6 weeks.